Key result
A 6-minute walk test distance <300 m predicted lower event-free survival compared to walking ≥300 m (62% vs 82%; P<0.0005) in patients with mild to moderate heart failure.
Why the study?
Does 6-minute walk test distance predict event-free survival in patients with mild to moderate congestive heart failure?
Cohort (n=214)
Does 6-minute walk test distance predict event-free survival in patients with mild to moderate congestive heart failure?
A 6-minute walk test distance of <300 m is a strong prognostic marker for subsequent cardiac death or heart transplantation in patients with mild to moderate heart failure.
Answers are grounded in this paper and cite their sources.
Supports 6MWT <300 m for risk stratification in mild-moderate HF; leaves open whether it should guide therapy or trial enrollment.
AIM: The study was designed to evaluate the prognostic value of the 6-min walk test (6MWT) in patients with mild to moderate congestive heart failure (CHF). METHODS AND RESULTS: Two hundred and fourteen patients (119 men and 95 women, mean age 64 years) were followed for a mean period of 34 months to assess event-free survival (death, heart transplantation). Sixty-six patients (34%) died (63 cardiovascular causes, 2 cancer and 1 stroke) and five patients underwent heart transplantation. For patients who walked <300 m during the 6MWT, survival was 62% compared with 82% in patients who walked 300-450 m or>450 m. With univariate analysis, NYHA class was the strongest predictor of death. LVEF (P<0.0001), aetiology of heart failure (P<0.001), LV filling pattern (P=0.002) and 6MWT distance (P<0.01) were all significantly related to survival. No significant relationship was found between survival, peak oxygen consumption or anaerobic threshold. Multivariate analysis using the Cox-stepwise regression model showed that LV fractional shortening (P<0.009) and 6MWT distance (P<0.0005) were the strongest prognostic markers. CONCLUSION: A 6MWT distance of <300 m is a simple and useful prognostic marker of subsequent cardiac death in unselected patients with mild to moderate CHF.
No takes yet. Share an insight, caveat, or question.
Rostagno et al. (2003) conducted a cohort in Mild to moderate congestive heart failure (CHF) (n=214). 6-minute walk test (6MWT) distance <300 m vs. 6MWT distance ≥300 m was evaluated on Event-free survival (death, heart transplantation) (p=<0.0005). A 6-minute walk test distance <300 m predicted lower event-free survival compared to walking ≥300 m (62% vs 82%; P<0.0005) in patients with mild to moderate heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: